Investment Shastra
Weekly Result Updates 19-05-2023

Q4FY23 Result Updates – 19 May 2023

Dear Readers,

Welcome to our weekly company result update note. We understand the importance of staying up-to-date with the latest financial developments of the companies you have invested in. That’s why we are committed to providing you with short and insightful information about the earnings and performance of the companies in our coverage.

In addition to the weekly company result update, after the end of the earnings season, we will also be sending you a quarterly sector result review. This will give you a broader understanding of how these sectors are performing and help you make informed decisions about your investments.

SBI

  Q4FY23 % Change YoY Comments
Advances 31,99,269 17.0%  
Deposits 44,23,777 9.2%  
Net Interest Income (NII) 40,392.5 29.5% NIM at 3.84%
Gross Non-Performing Asset (GNPA) 2.78% -118 bps  
Profit after tax (PAT) 16,694.5 83.2%  

Results were good on account of GNPA improvement.

Check, 10-Year X-ray Now!

Cipla

 

Q4FY23

YOY(%)

Comment

Revenue Net 5,739 9.1 Domestic formulation sales grew by 3.5% YoY
EBITDA 1,174 56.6  
EBITDA Margin 20.5% 620  
PAT 704 64.4  

Adjusted for COVID, growth was 14% YoY led by momentum across a portfolio of the One-India business. US sales came in at $204mn. International markets grew by 7% YoY, while SAGA reported a 13% decline. API saw a decline of 3% YoY.

At Par Result.

Check, 10-Year X-ray Now!

ITC

  Q4FY23 YoY(%) Comments
Revenue Net 16,150 5.5 FMCG revenue grew by 19.4% to 4,945 Cr
EBITDA 6,209 18.9  
EBITDA Margin 38.45% 626bps  
PAT 5087 21.4  

Good Result on account of increase in revenue and improvement in Margin across all segments.

Check, 10-Year X-ray Now!

Advanced Enzyme

 

Q4FY23

YOY (%)

Comment

Revenue 139 5.3 The Human Nutrition segment, which contributes ~63% to overall revenue and is even higher in terms of profit, continued to witness weakness on account of recessionary trends in the USA and inventory pile-up at the customers’ end. Ex-Human Nutrition, the portfolio grew by 13% YoY in 4QFY23.
EBITDA 44 9.5  
EBITDA Margin 31.8% 122bps  
PAT 32 27  

At Par Result, US business to drive forward margins.

Check, 10-Year X-ray Now!

Amber Enterprises

 

Q4FY23

YOY (%)

Comment

Revenue 3003 55 Led by an uptick in demand for RAC & components coupled with new customer additions.
EBITDA 204 62.4  
EBITDA Margin 6.8% 31bps Gross margin remained flat YoY mainly due to a change in product mix. However, better operating leverage resulted in an

EBITDA margin improvement

PAT 108 82.3  

Good Result driven by margin improvement.

Check, 10-Year X-ray Now!

Kajaria Ceramics

 

Q4FY23

YOY (%)

Comment

Revenue ( Consolidated) 1,205 9  
EBITDA 176 6  
EBITDA Margin 14.60% -46bps Improvement in EBITDA margin of 240bps on QOQ basis on account of decline in gas prices and cost optimization initiative.
PAT 108 13  

The decent result on account of easing in input costs.

Check, 10-Year X-ray Now!

Bank of Baroda

  Q4FY23 % Change YoY Comments
Advances 9,69,548 18.5% International advances grew by 29.9% to 173,988 Cr
Deposits 12,03,688 15.1%  
Net Interest Income (NII) 11,525 33.8% NIM at 3.53%
Gross Non-Performing Asset (GNPA) 3.79% -282 bps  
Profit after tax (PAT) 4,775 168.4%  

Results were good, with solid fundamentals on all metrics.

Check, 10-Year X-ray Now!

Bharti Airtel

  Q4FY23 % Change YoY Comments
Revenue 36,009 14.3% ARPU at 193, Enterprise segment grew by 14.5% to 4,785 Cr, 7.4 Mn 4G subscribers added
EBITDA 18,806 16.6% EBITDA margin at 52.2%
PAT 3,005 49.7%  

Stable results driven by growth in subscribers & enterprise segment.

Check, 10-Year X-ray Now!

Quess Corp Limited

Rs (Cr)

Q4FY23

YoY(%)

Comment

Revenue ( Consolidated) 4,440 17 Driven by WFM (up 16%), OAM (up 19%), and GTS (up 20%).
EBITDA 152 -18  
EBITDA Margin 3.42% -146bps Due to investments in Product Led Business.
PAT 30 -61  

At Par Result.

Check, 10-Year X-ray Now!

Container Corporation

  Q4FY23 % Change YoY Comments
Revenue 2,184 6.2%  
EBITDA 451 8.1% EBITDA margin at 20.6%
PAT 279 7.1%  

Subpar results on account of muted EXIM volumes.

Check, 10-Year X-ray Now!

CreditAccess Grameen

  Q4FY23 % Change YoY Comments
Advances 21,031 26.7%  
Net Interest Income (NII) 690 34.2% NIM at 12.2%
Gross Non-Performing Asset (GNPA) 1.21% -170 bps  
Profit after tax (PAT) 296 86%  

A solid set of results with improving metrics on all parameters.

Check, 10-Year X-ray Now!

core 50 superstars banner

Best Stocks From:

All Weather Alpha Case  Screener Alpha Cases  Business Houses Group


Join our Telegram Channel:
Stock Investing
Mutual Fund Investing

 


Join our Telegram Channel:
Stock Investing
Mutual Fund Investing

Need help on Investing? And more….Puchho Befikar

Why MoneyWorks4me | Call: 020 6725 8333 | Ebook | WhatsApp: 9860359463

*Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

*Disclaimer: The securities quoted are for illustration only and are not recommendatory

What’s your Reaction?
+1
0
+1
0
+1
0

Stay Informed: Subscribe to Our Newsletter for Key Updates

Team-MoneyWorks4me

A team of business leaders, equity research analysts & investment counsellors. Started in 2008; experienced in equity research, financial planning and portfolio management. Passionate about providing institutional quality research and advice to Retail Investors in a simple easy-to-understand-and-act manner.

Search

Archives

×